inv(16), CBFB-MYH11 Translocation | NeoGenomics Laboratories

Code

MOG-CMTX-01BV

Test

Active-Compendium

81401

Clinical

Pathology

Bone Marrow Aspirate: 2 mL in EDTA tube. 
Peripheral Blood: 5 mL in EDTA tube. 
Note: Test is RNA-based. Please select Extract & Hold - RNA if specimen hold service is desired.

Hematologic Diseases

Acute myeloid leukemia (AML)

Mon, 01/13/2025 - 12:00

Sat, 12/06/2025 - 12:00

Molecular

Global

Flag Active

True

Orderable Test Description

This test uses real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript. Positive results are reported as ratio of the amount of fusion transcript with the amount of transcript from a normal control gene. This assay identifies type A fusions, which account for >90% of fusions. Analytical sensitivity is 1 tumor cell in 10,000 normal cells.

Orderable Turn Around Time

7 Days

Keywords

inv 16

cbfb myh11

inv 16 cbfb

Meta Description

Real-time RT-PCR for quantitative detection of the inv(16) CBFB-MYH11 fusion transcript. Positive results are reported as ratio of the amount of fusion transcript with the amount of transcript from a normal control gene.

Orderable Biomarkers

CBFB-MYH11

NY Approved

False

Orderable Biomarkers JSON

{"Fluorescence In Situ Hybridization (FISH)": {"Translocation(s)": ["CBFB-MYH11"]}}

Keywords string

inv 16, cbfb myh11, inv 16 cbfb inv(16), CBFB-MYH11 Translocation

Title URL

inv16-cbfb-myh11-translocation

Clinical Significance

The assay detects and quantifies the CBFß (core binding factor ß chain)-MYH11 (myosin heavy chain 11 gene) fusion transcripts in bone marrow and peripheral blood in patients with acute myelomonocytic leukemia with abnormal eosinophils, M4E0.Which counts for approximately 10% of all acute myeloid leukemia (AML). Patients with inv (16) generally are associated with relatively good long-term, disease free survival. Confirmation of the diagnosis of this subtype of acute myeloid leukemia is very important due to its specific management.

In addition to confirming diagnosis, this assay is also recommended for monitoring minimal residual disease (MRD) and predicting relapse. For monitoring MRD, we recommend monitoring trends rather than the absolute ratio of a single measurement. It has been reported that the inv (16) translocation produces five types of fusion transcript (A, B, C, D and E). The type A accounts for more than 90% of cases detected. This assay detects type A fusion transcript only.

Storage and transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. Please select Extract & Hold - RNA if specimen hold service is desired.